In the biomarker substudy of the EARLY TAVR trial, baseline levels of NT-proBNP and hs-cTnT were associated with higher event rates, but did not significantly modify the relative benefit of early TAVR in asymptomatic patients with severe high-gradient aortic stenosis. The gene discussed is TNNT2; the disease is aortic stenosis.